Toxicity assessments

OTHER2 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center, Centre Hospitalier Universitaire de Nice

Conditions

Acute Myeloid LeukemiaGastrointestinal CancerSarcoma

Unknown Phase

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

RecruitingNCT05743426

UNC Lineberger Comprehensive Cancer CenterGastrointestinal Cancer, Sarcoma

Start: 2023-03-17End: 2036-01-01Target: 180Updated: 2026-03-30

Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

CompletedNCT06030089

Centre Hospitalier Universitaire de NiceAcute Myeloid Leukemia

Start: 2024-02-26End: 2025-03-03Updated: 2025-12-16

Related Papers

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

Blood2025-11-03